“Empowering Women Leading the Fight Against Cancer”
Most patients with newly diagnosed Ovarian cancer will have advanced disease. Nearly 70% of women relapse within 3 years of first-line treatment. There is a significant need for better first-line treatment to improve outcomes for women with advanced ovarian cancer. Approximately 50% of patients with high grade serous ovarian cancer have HRD. BRCA1 and BRCA2…
Pain remains one of the most prevalent and complex symptoms experienced by patients with breast cancer, arising from surgical interventions, chemotherapy, radiotherapy and metastatic disease, and significantly affecting quality of life and functional outcomes. The aim of this presentation is to highlight a structured, evidence-based and multidisciplinary approach to pain management across the continuum of…
The optimal extent of axillary surgery in breast cancer patients receiving neoadjuvant chemotherapy (NAC) remains controversial, particularly in the setting of increasing rates of nodal pathological complete response (ypN0) and the morbidity associated with axillary procedures. Identifying predictors of ypN0 may refine surgical decision-making and support selective de-escalation strategies. In this retrospective cohort study, 179…
The future of surgical oncology is being redefined by the integration of Artificial Intelligence (AI), Metaverse technologies, robotic-assisted surgery, laser tumor ablation, and metaverse-guided endoscopy. These innovations are collectively transforming cancer care by improving precision, safety, and efficiency in surgical interventions. AI contributes to enhanced diagnostic accuracy, predictive analytics, optimized surgical planning, and real-time decision…
Ovarian cancer remains one of the most lethal Gynecologic malignancies worldwide due to late-stage diagnosis and limited targeted therapeutic options. Folate Receptor Alpha (FRα), a glycosylphosphatidylinositol- anchored membrane protein involved in folate transport, is overexpressed in a large proportion of epithelial ovarian carcinomas, particularly high- grade serous carcinoma, while its expression in normal tissues remains…